CDTX - Cidara Therapeutics Year-over-year net earnings per share growth for the last 12 months

CDTX (Cidara Therapeutics) - company brandmark

Cidara Therapeutics (CDTX) profitability is supported by the success of Rezzayo and its alliance with Janssen. The quarterly EPS trend reflects current volatility, with the metric standing at -26.70. The company develops advanced immunotherapies to combat infections. However, the loss of a key counterparty and strict FDA oversight create risks for ecosystem development, necessitating the urgent procurement of new investment agreements.

Cidara Therapeutics, Inc. (CDTX) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 01/17/2026

Summary analytical data breakdowns for cidara.com (CDTX)

- market value and analyst target forecast:
- market capitalization statistics:
Summary company analysis:Cidara Therapeutics Inc - CDTX
Flagship merchandise of Cidara Therapeutics

This indicator assesses the efficiency of net income generation per share on a quarterly basis. This quarterly EPS chart visualizes the rate of change in the company's equity. The metric is calculated by comparing the bottom-line financial result with the number of shares outstanding. For Cidara Therapeutics (CDTX), this figure reflects the resource burn rate. The absence of revenue makes profit dynamics dependent on one-time partner tranches.

Competitor analysis

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Novavax, Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CVAC|Quarterly EPS earnings growth valneva.com|Year-over-year net earnings per share growth for the last 12 months VIR (Vir Biotechnology)|Year-over-year net earnings per share change for the last twelve months SIGA Technologies Inc|Year-over-year earnings per share growth for the last twelve months Emergent Bio EBS|Quarterly EPS earnings growth Atea Pharmaceuticals AVIR|IVVD - Year-over-year earnings per share growth for the last twelve months|ENTA (Enanta Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)